Corcept Therapeutics INC Form 4 insider transactions
NASDAQ
Director David L. Mahoney of Corcept Therapeutics exercised stock options, disposed of shares to cover exercise costs and tax liabilities, and transferred shares to a family trust.
NASDAQ
Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on April 4, 2024, according to a Form 4 filing with the SEC.
NASDAQ
Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, reports the acquisition and disposal of company stock on April 1, 2024, pursuant to a 10b5-1 plan.
NASDAQ
Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics under a pre-arranged 10b5-1 trading plan.
NASDAQ
Form 4: Corcept Therapeutics Executive Sean Maduck Executes Stock Option and Sells Shares Under 10b5-1 Plan
Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold shares of Corcept Therapeutics under a pre-arranged 10b5-1 trading plan.
NASDAQ
Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold shares of Corcept Therapeutics (CORT) common stock on March 18 and 19, 2024, according to a Form 4 filing with the SEC.
NASDAQ
Joseph Douglas Lyon, Chief Accounting Officer of Corcept Therapeutics, reports stock transactions including share withholding for tax obligations, stock purchases, and vesting of restricted stock units.
NASDAQ
Sean Maduck, President of Corcept Endocrinology, reports stock transactions including tax withholding, purchase plan acquisitions, and holdings in related entities.
NASDAQ
William Guyer, Chief Development Officer of Corcept Therapeutics, reports the disposal of 604 shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Atabak Mokari, CFO of Corcept Therapeutics, reports transactions involving common stock, including shares withheld for tax obligations, purchases under a company purchase plan, and vesting of restricted stock awards.
NASDAQ
Director Daniel N. Swisher Jr. of Corcept Therapeutics exercised stock options and sold the acquired shares on March 1, 2024, according to a Form 4 filing with the SEC.
NASDAQ
Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports stock transactions including tax withholding, purchase plan acquisitions, and restricted stock awards.